{"id":"sb213503-lot-2","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Nasopharyngitis"}]},"_chembl":{"chemblId":"CHEMBL5853519","moleculeType":null,"molecularWeight":"319.43"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"CCR3 is highly expressed on eosinophils and plays a central role in their migration to sites of inflammation. By antagonizing CCR3, SB213503 reduces eosinophil infiltration into airways and tissues, thereby decreasing eosinophil-mediated inflammation. This mechanism is particularly relevant in eosinophilic airway diseases where eosinophil accumulation drives pathology.","oneSentence":"SB213503 is a selective antagonist of the chemokine receptor CCR3, which blocks eosinophil recruitment and activation in inflammatory airway diseases.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:33:35.706Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma with eosinophilic phenotype"},{"name":"Eosinophilic airway inflammation"}]},"trialDetails":[{"nctId":"NCT00148941","phase":"PHASE3","title":"Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-01-06","conditions":"Tetanus, Acellular Pertussis, Diphtheria","enrollment":4209}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":86,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GSK Biologicals combined diphteria, tetanus, acellular pertussis and inactivated poliovirus lot 2 vaccine"],"phase":"phase_3","status":"active","brandName":"SB213503 lot 2","genericName":"SB213503 lot 2","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"SB213503 is a selective antagonist of the chemokine receptor CCR3, which blocks eosinophil recruitment and activation in inflammatory airway diseases. Used for Asthma with eosinophilic phenotype, Eosinophilic airway inflammation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}